Alzheimer's Clinical Trials in Lancaster

View 40 new treatments for Alzheimer's in Lancaster, CA, and other areas near me, such as Palmdale. Every day, Power helps hundreds of alzheimers patients connect with leading medical research.
View 44 trials in Lancaster
Filter (44)

AVP-786 for Alzheimer's-related Agitation

Avanir Clinic, Panorama City + 6 more

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Semaglutide for Early Alzheimer's Disease

Novo Nordisk Clinic, Simi Valley + 11 more

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Clinical Transparency (Dept. 2834)
Study Director

KarXT for Alzheimer's-Related Psychosis

Karuna Clinic, Encino + 4 more

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 or CN012-0027 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

Masupirdine for Agitation in Alzheimer's Disease

Suven Life Sciences Clinic, Encino + 2 more

This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

AVP-786 for Agitation in Alzheimer's Disease

Avanir Clinic, Pasadena + 2 more

This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

KarXT for Psychosis in Alzheimer's Disease

Karuna Clinic, Los Angeles + 3 more

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director

KarXT for Alzheimer's-Related Psychosis

Karuna Clinic, Canoga Park + 5 more

This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Paul Yeung, MD, MPH
Study Director

Remternetug for Alzheimer's Disease

Eli Lilly Clinic, Sherman Oaks + 1 more

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Donanemab for Early Alzheimer's Disease

Eli Lilly Clinic, Pasadena + 9 more

This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

AR1001 for Alzheimer's Disease

AriBio Clinic, Northridge + 2 more

This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Sharon Sha, MD, MS
Principal Investigator
Page 1 of 5

Frequently Asked Questions

How much do alzheimer's clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do alzheimer's clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Lancaster, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.